4D Molecular Therapeutics (FDMT) Other financing activities (2020 - 2024)

4D Molecular Therapeutics (FDMT) has 5 years of Other financing activities data on file, last reported at $3.1 million in Q1 2024.

• On a quarterly basis, Other financing activities rose 119.84% year-over-year to $3.1 million in Q1 2024; TTM through Mar 2024 was $4.6 million, a 64.58% increase from a year earlier, with the FY2021 full-year figure at $433000.0, changed N/A from the prior year.
• Other financing activities for Q1 2024 stood at $3.1 million, up from -$758000.0 in the prior quarter.
• Over the last five years, Other financing activities for FDMT reached as high as $3.1 million in Q1 2024 and fell as low as -$758000.0 in Q2 2023.
• Historically, Other financing activities has averaged $740428.6 across 5 years, with a median of $433000.0 in 2021.
• Across the five-year window, Other financing activities soared 1880.0% in 2021 and jumped 61.83% in 2023, its largest moves.
• Year by year, Other financing activities stood at $5000.0 in 2020, then surged by 8560.0% to $433000.0 in 2021, then soared by 102.08% to $875000.0 in 2022, then tumbled by 186.63% to -$758000.0 in 2023, then soared by 510.69% to $3.1 million in 2024.
• Per Business Quant data, the three most recent Other financing activities figures were $3.1 million in Q1 2024, -$758000.0 in Q2 2023, and $1.4 million in Q1 2023.